首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2019年 11期“中国肝移植的发展与创新” => 肝脏肿瘤 =>金龙胶囊联合西医疗法..
金龙胶囊联合西医疗法治疗原发性肝癌效果的Meta分析
Clinical effect of Jinlong capsules combined with Western medicine treatment in treatment of primary liver cancer: A Meta-analysis
文章发布日期:2019年09月29日  来源:  作者:时克, 王晓静, 王宪波  点击次数:230次  下载次数:49次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】: 目的 探讨金龙胶囊联合西医疗法治疗中晚期原发性肝癌的疗效及不良反应。方法 通过计算机检索 PubMed、The Cochrane Library、中国知网、万方数据库、中国生物医学文献数据库、维普中文科技期刊数据库2019年5月之前的文献,全面收集金龙胶囊联合西医疗法治疗原发性肝癌的随机对照试验,干预组为金龙胶囊联合西医治疗,对照组为单纯西医治疗。对纳入的文献提取资料及质量评价,通过 RevMan 5.3软件,采用固定或随机效应模型进行Meta分析。结果 纳入26篇文献,共2318 例患者,干预组1175例,对照组1143例。分析结果显示,金龙胶囊联合西医疗法与单纯西医疗法相比,能提高有效率[相对危险度(RR)=1.36,95%可信区间(95%CI):1.25~1.49,P<0.001]、1年生存率(RR=1.29,95%CI:1.14~1.47,P<0.001)、KPS评分(RR=1.37,95%CI:1.19~1.59,P<0.001)和外周血CD3+T淋巴细胞[均数差(MD)=11.18,95%CI:2.68~19.68,P=0.01]、CD4+T淋巴细胞 (MD=6.43,95%CI:3.82~9.05,P<0.001)、CD4+/ CD8+T淋巴细胞水平(MD=0.31,95%CI:0.26~0.36,P<0.001);降低进展率(RR=0.41,95%CI:0.29~0.57,P<0.001)、白细胞下降率(RR=0.65,95%CI:0.57~0.75,P<0.001)、胃肠反应发生率(RR=0.72,95%CI:0.59~0.88,P=0.001)和外周血CD8+T淋巴细胞水平(MD=-4.68,95%CI:-5.84~-3.51,P<0.001)。结论 金龙胶囊联合西医疗法治疗中晚期原发性肝癌的疗效显著,不良反应较少,具有临床推广价值。
【Abstract】: Objective To investigate the clinical effect and adverse events of Jinlong capsules combined with Western medicine treatment in the treatment of advanced primary liver cancer. Methods PubMed, The Cochrane library, CNKI, Wanfang Data, CBM, and VIP were searched for randomized controlled trials (RCTs) on Jinlong capsules combined with Western medicine treatment in the treatment of advanced primary liver cancer published up to May 2019. The patients treated with Jinlong capsules combined with Western medicine treatment were enrolled as intervention group, and those treated with Western medicine treatment alone were enrolled as control group. Data extraction and quality assessment were performed, and RevMan 5.3 was used to perform the Meta-analysis with a fixed or random effects model. Results A total of 26 RCTs were included, with a total of 2318 patients (1175 patients in the intervention group and 1143 patients in the control group). The results of the Meta-analysis showed that compared with Western medicine treatment alone, Jinlong capsules combined with Western medicine treatment had significant increases in response rate (relative risk [RR]=1.36, 95% confidence interval [CI]: 1.25-1.49, P<0.001), 1-year survival rate (RR=1.29, 95%CI: 1.14-1.47, P<0.001), Karnofsky Performance Scale score (RR=1.37, 95%CI: 1.19-1.59, P<0.001), peripheral blood CD3+ T lymphocytes (mean difference [MD]=11.18, 95%CI: 2.68-19.68, P=0.01), CD4+ T lymphocytes (MD=6.43, 95%CI: 3.82-9.05, P<0.001), and CD4+/CD8+ ratio (MD=0.31, 95%CI: 0.26-0.36, P<0.001), as well as significant reductions in rate of progression (RR=0.41, 95%CI: 0.29-0.57, P<0.001), rate of leucopenia (RR=0.65, 95%CI: 0.57-0.75, P<0.001), incidence rate of gastrointestinal reactions (RR=0.72, 95%CI: 0.59-0.88, P=0.001), and peripheral blood CD8+ T lymphocytes (MD=-4.68, 95% CI: -5.84 to -3.51, P<0.001). ConclusionJ inlong capsules combined with Western medicine treatment has a marked clinical effect in the treatment of advanced primary liver cancer with few adverse events and thus holds promise for clinical application.
【关键字】:肝肿瘤; 金龙胶囊; 中西医结合; 治疗结果; Meta分析
【Key words】:liver neoplasms; Jinlong capsules; integrated TCM WM; treatment outcome; Meta-analysis
【引证本文】:SHI K, WANG XJ, WANG XB. Clinical effect of Jinlong capsules combined with Western medicine treatment in treatment of primary liver cancer: A meta-analysis[J]. J Clin Hepatol, 2019, 35(11): 2495-2501. (in Chinese)
时克, 王晓静, 王宪波. 金龙胶囊联合西医疗法治疗原发性肝癌效果的Meta分析[J]. 临床肝胆病杂志, 2019, 35(11): 2495-2501.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号